Assessment of the availability of medicines under the reimbursement program for patients with type 2 diabetes in Vinnytsya region

Aim: assessment of drug availability under the reimbursement program for patients with type 2 diabetes in Vinnytsya region. Materials and methods of research. A set of regulatory legal acts on the organization of pharmaceutical support for patients with diabetes in Ukraine; data from scientific literature on the problems of organizing effective pharmaceutical care for patients with diabetes in Ukraine and in the world; patients with type 2 diabetes, doctors who provide primary medical care (family doctors), the State Register of Drugs (2024), the official Internet resource of the National Health Insurance Fund. Methods: historical; logical; comparative, semantic, bibliographical; graphical; mathematical and statistical. Results. As a result of the study, a comprehensive assessment of the availability of drugs under the reimbursement program for patients with type 2 diabetes was carried out, which included an analysis of the current state of provision for patients with type 2 diabetes and an analysis of e-prescriptions created under the reimbursement program for 2019-2024. It was found that 45 names were registered by trade name (TN) - 80.0 % based on metformin (A10BA02), 7 names by TN (13.0 %) based on gliclazide (A10BB09), and 3 names by TN (7.0 %) based on glibenclamide (A10BB01). According to the results of the analysis of e-prescriptions created under the reimbursement program over the past 6 years, the leader among diseases in terms of the number of prescriptions were cardiovascular diseases – 2 481 626 e-prescriptions. The total number of prescriptions over the six years was 744 952. Metformin became the leading drug in terms of prescription frequency – 540 384 e-prescriptions were written for it. The largest number of prescriptions was written in cities – 431 821, which is more than 50 % of the total. In rural areas, this figure is significantly lower – 199 180, and in urban settlements – 113 951, which indicates an uneven distribution of access to treatment and, probably, a higher prevalence of applications in cities. There is a trend towards an increase in the number of prescriptions issued (from 103 711 e-prescriptions in 2019 to 140 412 e-prescriptions in 2024), which may indicate improved accessibility of medical services and medicines for patients. Conclusions. As a result of the study, a positive trend was established in the number of e-prescriptions issued for oral hypoglycemic drugs in the Vinnytsya region, which indicates an increase in the availability of pharmaceutical care for chronic patients with type 2 diabetes and an improvement in the healthcare system as a whole.